Ambrx Biopharma, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Ambrx Biopharma, Inc.
Finance Watch: Biotech Valuations Seesaw On Bank Failure, Pharma M&A
Public Company Edition: The closure of Silicon Valley Bank sank biotech stocks in the first full week of March, but valuations rose the next week when two big acquisitions were announced. Also, J&J’s consumer health spinout sold $7.75bn in notes ahead of its future IPO and Karuna grossed $400m in a follow-on offering.
Deals In 2023: Partnerships And Modest M&A
Mid-sized M&A, collaborations, creative financing, and biotech consolidation will feature in 2023. IPOs and follow-ons play bit-parts.
BioNTech Beefs Up AI/ML Investment With InstaDeep Buy
The company is spending up to £562m to acquire artificial intelligence/machine learning provider InstaDeep, which it has partnered with since 2020, as competitor Moderna has made digital technology a cornerstone of its strategy.
Zymeworks Deal Expands Jazz’s Potential Oncology Presence
The deal focuses on the HER2-targeting bispecific antibody zanidatamab, in development for multiple solid tumor indications expressing HER2.
- Drug Delivery
- Drug Discovery Technologies
- Synthesis Technologies, Production Processes
- Other Names / Subsidiaries
- Ambrx, Inc.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.